Company news

Patrys Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PAT-DX1 Improves Survival in Model of Pancreatic Cancer

July 25, 2021

Full size deoxymab PAT-DX3 crosses the blood brain barrier

July 11, 2021

Response to ASX Query

June 23, 2021

Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight

June 16, 2021

Paper highlights PAT-DX1 as potential brain cancer treatment

June 15, 2021

Patrys receives R&D Tax Incentive refund

June 9, 2021

Appendix 4C - Quarterly - 31 March 2021

April 27, 2021

New United States patent granted for Patrys deoxymab assets

March 30, 2021

Appendix 4D - Half Year Accounts - 31 December 2020

February 19, 2021

Patrys Successfully Establishes PAT-DX1 Stable Cell Line

February 9, 2021

Appendix 4C - Quarterly - 31 December 2020

January 27, 2021

$7.3M Capital Raising

November 8, 2020

Investor Presentation - November 2020 - Updated

November 5, 2020

Investor Presentation - November 2020

November 4, 2020

Appendix 4C - Quarterly - 30 September 2020

October 25, 2020

First patent granted for Deoxymab-nanoparticles

October 5, 2020

Patrys Adds Full Human Antibody to Deoxymab Portfolio

September 28, 2020

Patrys adds full human antibody to Deoxymab portfolio

September 27, 2020

Appendix 4E and 2020 Annual Report

August 24, 2020

Entitlement Offer Results and Shortfall Notification

August 3, 2020

Appendix 4C - Quarterly - 30 June 2020

July 30, 2020

$4.29 Million Fully Underwritten Rights Issue

June 22, 2020

Investor Presentation - June 2020

June 17, 2020

Appendix 4C - Quarterly - 31 March 2020

April 26, 2020

PAT-DX1 mechanism for crossing blood brain barrier confirmed

March 15, 2020

PAT-DX1-NP crosses BBB and targets tumours

March 1, 2020

Appendix 4D - Half Year Accounts - 31 December 2019

February 24, 2020

Appendix 4C - Quarterly - 31 December 2019

January 29, 2020

Appendix 4C - Quarterly - 30 September 2019

October 28, 2019

Appendix 4E and 2019 Annual Report

August 22, 2019

Appendix 4C - Quarterly - 30 June 2019

July 29, 2019

PAT-DX1 significantly improves survival in aggressive GBM

July 21, 2019

Europe grants patent for Deoxymab 3E10

July 17, 2019

PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy

May 29, 2019

Appendix 4C - Quarterly - 31 March 2019

April 23, 2019

Market Update

March 29, 2019

Appendix 4D - Half Year Accounts - 31 December 2018

February 20, 2019

Appendix 4C - Quarterly - 31 December 2018

January 30, 2019

PAT-DX1 Suppresses Breast Cancer Brain Metastases

December 19, 2018

Appendix 4C - Quarterly - 30 September 2018

October 30, 2018

Settlement of Manufacturing Claims

October 24, 2018

PAT-DX1 Clinical Target Indications Confirmed

October 4, 2018

Patrys and WEHI Awarded Grant

August 28, 2018

Appendix 4E and 2018 Annual Report

August 24, 2018

Patent Granted for Pre-clinical IgM Candidate PAT-LM1

August 1, 2018

Appendix 4C - Quarterly - 30 June 2018

July 25, 2018

Preliminary PAT-DX1 pharmacokinetics

July 5, 2018

China and Japan both grant patents for Deoxymab 3E10

July 3, 2018

PAT-DX1 Targets and Kills Brain Cancer Stem Cells

May 30, 2018

Patrys Increases Capital Raising to $4.6 million

May 20, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 43 decks. Every deck is listed under its year.